Stocktoria
MANNKIND CORP MNKD
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2004-07-28
MANNKIND CORP financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $349.0M | $285.5M | $199.0M | $99.8M | $75.4M |
| SG&A expense | $144.1M | $94.3M | $94.3M | $91.5M | $77.4M |
| Operating income | $38.8M | $72.6M | $8.7M | -$64.1M | -$47.0M |
| Interest expense | — | — | $15.2M | $15.0M | $15.2M |
| Income tax | -$4.5M | $2.9M | $1.6M | $0 | $0 |
| Net income | $5.9M | $27.6M | -$11.9M | -$87.4M | -$80.9M |
| EPS (diluted) | $0.02 | $0.10 | $-0.04 | $-0.34 | $-0.32 |
| Operating cash flow | $18.3M | $42.5M | $34.1M | -$80.7M | -$61.7M |
| Free cash flow | $13.7M | $32.8M | -$8.3M | -$88.3M | -$73.2M |
| Cash & equivalents | $74.9M | $46.3M | $238.5M | $69.8M | $124.2M |
| Inventory | $35.3M | $27.9M | $28.5M | $21.8M | $7.2M |
| Total assets | $792.2M | $393.8M | $475.2M | $295.3M | $321.2M |
| Total liabilities | $843.2M | $472.7M | $721.4M | $545.8M | $530.5M |
| Shareholders' equity | -$51.0M | -$78.8M | -$246.2M | -$250.5M | -$209.3M |
Source: SEC EDGAR filings · CIK 0000899460 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.